Dr Reddys Laboratories (RDY) EBT (2009 - 2023)

Dr Reddys Laboratories' EBT history runs 15 years deep, the most recent figure standing at $230.0 million for Q2 2023.

• On a quarterly basis, EBT changed N/A year-over-year to $230.0 million in Q2 2023; TTM through Jun 2023 was $785.0 million, a N/A change from a year earlier, with the FY2026 full-year figure at $584.0 million, down 35.11% from the prior year.
• EBT climbed to $230.0 million in Q2 2023 per RDY's latest filing, from $222.0 million in the prior quarter.
• Across five years, EBT topped out at $230.0 million in Q2 2023 and bottomed at -$72.0 million in Q3 2020.
• The 5-year median for EBT is $119.0 million (2020), against an average of $123.9 million.
• Across the five-year window, EBT sank 188.89% in 2020 and jumped 44.92% in 2021, its largest moves.
• Year by year, EBT stood at $81.0 million in 2019, then sank by 188.89% to -$72.0 million in 2020, then surged by 337.5% to $171.0 million in 2021, then slipped by 5.26% to $162.0 million in 2022, then soared by 41.98% to $230.0 million in 2023.
• Per Business Quant, the three latest RDY EBT figures stand at $230.0 million (Q2 2023), $222.0 million (Q1 2023), and $162.0 million (Q4 2022).